Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.09
CPHD's Cash to Debt is ranked higher than
62% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. CPHD: 1.09 )
CPHD' s 10-Year Cash to Debt Range
Min: 0.99   Max: 11006.5
Current: 1.09

0.99
11006.5
Equity to Asset 0.47
CPHD's Equity to Asset is ranked higher than
62% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. CPHD: 0.47 )
CPHD' s 10-Year Equity to Asset Range
Min: 0.47   Max: 0.92
Current: 0.47

0.47
0.92
F-Score: 3
Z-Score: 5.64
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -5.57
CPHD's Operating margin (%) is ranked higher than
68% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. CPHD: -5.57 )
CPHD' s 10-Year Operating margin (%) Range
Min: -233.91   Max: 1.37
Current: -5.57

-233.91
1.37
Net-margin (%) -8.12
CPHD's Net-margin (%) is ranked higher than
67% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. CPHD: -8.12 )
CPHD' s 10-Year Net-margin (%) Range
Min: -220.28   Max: 0.95
Current: -8.12

-220.28
0.95
ROE (%) -11.26
CPHD's ROE (%) is ranked higher than
66% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. CPHD: -11.26 )
CPHD' s 10-Year ROE (%) Range
Min: -85.87   Max: 1.44
Current: -11.26

-85.87
1.44
ROA (%) -6.05
CPHD's ROA (%) is ranked higher than
68% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. CPHD: -6.05 )
CPHD' s 10-Year ROA (%) Range
Min: -61.04   Max: 1.04
Current: -6.05

-61.04
1.04
ROC (Joel Greenblatt) (%) -13.92
CPHD's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. CPHD: -13.92 )
CPHD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -619.62   Max: 6.69
Current: -13.92

-619.62
6.69
Revenue Growth (%) 18.70
CPHD's Revenue Growth (%) is ranked higher than
96% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. CPHD: 18.70 )
CPHD' s 10-Year Revenue Growth (%) Range
Min: -15.4   Max: 56.7
Current: 18.7

-15.4
56.7
EBITDA Growth (%) -16.20
CPHD's EBITDA Growth (%) is ranked higher than
63% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CPHD: -16.20 )
CPHD' s 10-Year EBITDA Growth (%) Range
Min: -38.8   Max: 8.7
Current: -16.2

-38.8
8.7
EPS Growth (%) 39.20
CPHD's EPS Growth (%) is ranked higher than
95% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. CPHD: 39.20 )
CPHD' s 10-Year EPS Growth (%) Range
Min: -37.2   Max: 39.2
Current: 39.2

-37.2
39.2
» CPHD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CPHD Guru Trades in Q4 2013

PRIMECAP Management 2,179,200 sh (+1.49%)
Ron Baron 882,500 sh (unchged)
Caxton Associates Sold Out
Columbia Wanger 8,360,000 sh (-0.35%)
Mario Gabelli 238,500 sh (-2.45%)
» More
Q1 2014

CPHD Guru Trades in Q1 2014

PRIMECAP Management 2,270,400 sh (+4.19%)
Ron Baron 889,830 sh (+0.83%)
Mario Gabelli 235,500 sh (-1.26%)
Columbia Wanger 7,467,000 sh (-10.68%)
» More
Q2 2014

CPHD Guru Trades in Q2 2014

Ron Baron 902,506 sh (+1.42%)
Columbia Wanger 7,467,000 sh (unchged)
Mario Gabelli 235,000 sh (-0.21%)
PRIMECAP Management 2,255,200 sh (-0.67%)
» More
Q3 2014

CPHD Guru Trades in Q3 2014

Columbia Wanger 7,745,200 sh (+3.73%)
Ron Baron 913,196 sh (+1.18%)
PRIMECAP Management 2,255,200 sh (unchged)
Mario Gabelli 234,500 sh (-0.21%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2013-09-30 Add 561.64%0.14%$33.66 - $39.31 $ 49.7938%882500
Andreas Halvorsen 2013-03-31 Sold Out 0.59%$32.75 - $39.16 $ 49.7937%0
Ron Baron 2012-12-31 New Buy0.03%$28.72 - $35.71 $ 49.7955%123586
Andreas Halvorsen 2012-09-30 Add 141.24%0.37%$31.97 - $45.88 $ 49.7930%2591610
Andreas Halvorsen 2012-06-30 New Buy0.39%$34.8 - $44.96 $ 49.7928%1074300
George Soros 2011-09-30 Sold Out 0.0029%$30.18 - $40.77 $ 49.7942%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.70
CPHD's P/B is ranked higher than
60% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. CPHD: 9.70 )
CPHD' s 10-Year P/B Range
Min: 2.25   Max: 21.88
Current: 9.7

2.25
21.88
P/S 7.80
CPHD's P/S is ranked higher than
62% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. CPHD: 7.80 )
CPHD' s 10-Year P/S Range
Min: 1.76   Max: 21.88
Current: 7.8

1.76
21.88
EV-to-EBIT -134.19
CPHD's EV-to-EBIT is ranked higher than
72% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CPHD: -134.19 )
CPHD' s 10-Year EV-to-EBIT Range
Min: -21113.7   Max: 744.4
Current: -134.19

-21113.7
744.4
Current Ratio 4.66
CPHD's Current Ratio is ranked higher than
85% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. CPHD: 4.66 )
CPHD' s 10-Year Current Ratio Range
Min: 1.49   Max: 15.23
Current: 4.66

1.49
15.23
Quick Ratio 3.47
CPHD's Quick Ratio is ranked higher than
81% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. CPHD: 3.47 )
CPHD' s 10-Year Quick Ratio Range
Min: 0.89   Max: 14.9
Current: 3.47

0.89
14.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.30
CPHD's Price/Tangible Book is ranked higher than
67% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. CPHD: 11.30 )
CPHD' s 10-Year Price/Tangible Book Range
Min: 2.1   Max: 20.68
Current: 11.3

2.1
20.68
Price/DCF (Projected) 34.30
CPHD's Price/DCF (Projected) is ranked higher than
80% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CPHD: 34.30 )
CPHD' s 10-Year Price/DCF (Projected) Range
Min: 17.83   Max: 94.71
Current: 34.3

17.83
94.71
Price/Median PS Value 1.10
CPHD's Price/Median PS Value is ranked higher than
76% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. CPHD: 1.10 )
CPHD' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 4.11
Current: 1.1

0.35
4.11
Earnings Yield (Greenblatt) -0.70
CPHD's Earnings Yield (Greenblatt) is ranked higher than
71% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. CPHD: -0.70 )
CPHD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.7   Max: 0.4
Current: -0.7

-0.7
0.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:XEP.Germany,
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
» More Articles for CPHD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: SeaCube, Hasbro, Cepheid, Honeywell Apr 28 2013 
Weekly CFO Sales Highlight: CLB, CPHD, ALXN, RDEA, BCR Jul 31 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 28 2011 
CEPHEID Reports Operating Results (10-K) Feb 24 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 15 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares Feb 08 2011 
CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares Dec 09 2010 
CEPHEID Reports Operating Results (10-Q) Nov 04 2010 
CEPHEID Reports Operating Results (10-Q) Aug 04 2010 
CEPHEID Reports Operating Results (10-Q) May 04 2010 

More From Other Websites
Top Medical Stocks: Cepheid Diagnostics Sales Strong Dec 02 2014
Cepheid Wins FDA Clearance for Xpert Norovirus Test Dec 02 2014
HTML PDF Dec 01 2014
HTML PDF Dec 01 2014
HTML PDF Dec 01 2014
Cepheid Receives FDA Clearance for Xpert Norovirus, the First On-Demand Molecular Test for Detection... Dec 01 2014
Cepheid Gets FDA Clearance for Xpert Flu/RSV XC Test Nov 25 2014
Cepheid Receives FDA Clearance for Xpert Flu/RSV XC Nov 24 2014
Cepheid Receives FDA Clearance for Xpert Flu/RSV XC Nov 24 2014
Cepheid to Webcast Upcoming Financial Presentations Nov 24 2014
CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers Nov 20 2014
Cepheid to Webcast Upcoming Financial Presentations Nov 20 2014
Cepheid Shines in Global Market, Raises Revenue Outlook Nov 13 2014
Thu., Nov. 13: Watch Wal-Mart on Mixed Earnings Nov 13 2014
Cepheid receives grant to develop Ebola diagnostic test Nov 13 2014
Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic Nov 13 2014
Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic Nov 13 2014
CEPHEID Financials Nov 11 2014
10-Q for Cepheid Nov 06 2014
CEPHEID Files SEC form 10-Q, Quarterly Report Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK